BiotechTube

Tirbanibulin 2.5 mg ointment

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Jan 20, 2023 → Jan 19, 2024

NCT ID
NCT05741294

About Tirbanibulin 2.5 mg ointment

Tirbanibulin 2.5 mg ointment is a approved stage product being developed by Almirall for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05741294. Target conditions include Actinic Keratosis.

What happened to similar drugs?

6 of 20 similar drugs in Actinic Keratosis were approved

Approved (6) Terminated (1) Active (14)
✅fluorouracil cream 0.5%SanofiApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
✅TirbanibulinAlmirallApproved
✅Ameluz 10% Topical GelBiofronteraApproved
🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05741294ApprovedCompleted

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
35
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
29
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
29
Investigational Treatment + Active comparatorNovartisPhase 2
35
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
40
FluorouracilSanofiPhase 1/2
32
fluorouracil cream 0.5%SanofiApproved
43
Imiquimod + DiclofenacViatrisApproved
40
Imiquimod 5 % CreamViatrisPhase 2
32
ImiquimodViatrisPre-clinical
23
Aldara (Imiquimod)ViatrisPhase 3
37
Imiquimod + DiclofenacViatrisApproved
40
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
34
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
41
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
34